Lopinavir/ritonavir/rocuronium bromide interactionMyopathy following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1843卷 / 1期

关键词：

D O I：

10.1007/s40278-021-91333-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：231 / 231

相关论文

共 50 条

[31] TocilizumabAnaphylaxis following off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 397 - 397
[32] MirtazapineTachyphylaxis following off-label use: case report
Reactions Weekly, 2018, 1703 (1) : 182 - 182
[33] RituximabPancytopenia following off-label use: case report
Reactions Weekly, 2020, 1807 (1) : 176 - 176
[34] DexamethasoneMucormycosis following off-label use: case report
Reactions Weekly, 2023, 1956 (1) : 181 - 181
[35] SintilimabFasciitis following off-label use: case report
Reactions Weekly, 2021, 1884 (1) : 391 - 391
[36] HydroxychloroquineEosinophilia following off-label use: case report
Reactions Weekly, 2021, 1867 (1) : 204 - 204
[37] GlibenclamideHypoglycaemia following an off-label use : case report
Reactions Weekly, 2021, 1866 (1) : 190 - 190
[38] HydroxychloroquineHaemolysis following off-label use: case report
Reactions Weekly, 2021, 1836 (1) : 376 - 376
[39] DaratumumabHypogammaglobulinemia following off-label use: case report
Reactions Weekly, 2020, 1802 (1) : 114 - 114
[40] DapsoneMethaemoglobinaemia following off-label use: case report
Reactions Weekly, 2021, 1843 (1) : 130 - 130

← 1 2 3 4 5 →